Á¤±ÔÇÏ ±³¼ö, ´ëÇѽŰæ¿Ü°úÇÐȸ¡®ÀÌ¿µ¿ìÇмú»ó¡¯ ¼ö»ó

´º½ºÀÏÀÚ: 2021³â10¿ù20ÀÏ 09½Ã56ºÐ

³úÁ¾¾ç ƯÀÌ ¹ÙÀÌ¿À¸¶Ä¿ ¹ß±¼, ³úÁ¾¾ç Ç¥Àû Ç×¾ÏÄ¡·á °¡´É¼º Á¦½Ã

[º¸°ÇŸÀÓÁî] °í·Á´ë ±¸·Îº´¿ø ½Å°æ¿Ü°ú Á¤±ÔÇÏ ±³¼ö(»çÁø)°¡ Áö³­ 14~16ÀÏ ¼Ûµµ¿¡¼­ °³ÃÖµÈ ‘Á¦61Â÷ ´ëÇѽŰæ¿Ü°úÇÐȸ Ãß°èÇмú´ëȸ(KNS 2021)’¿¡¼­ ‘ÀÌ¿µ¿ì Çмú»ó’À» ¼ö»óÇß´Ù.

Á¤ ±³¼ö´Â ‘¾Ç¼º ½Å°æ±³Á¾¿¡ ´ëÇÑ ¾à¹°Àü´Þ ´ë¾ÈÇ¥Àû ¹× ¾ÏÁø´Ü-¿¹ÈÄ ¹ÙÀÌ¿À¸¶Ä¿·Î¼­ÀÇ ÇǺê·Î³Øƾ ¿¢½ºÆ®¶ó µµ¸ÞÀÎ B(Extra-domain B of fibronectin as an alternative target for drug delivery and a cancer diagnostic and prognostic biomarker for malignant glioma)’¶ó´Â ÁÖÁ¦ÀÇ ³í¹®À¸·Î ½Å°æ¿Ü°úÇÐ ±âÃÊ ºÐ¾ß ¿ì¼ö ³í¹®¿¡ ¼ö¿©µÇ´Â ÀÌ¿µ¿ì Çмú»óÀ» ¼ö»óÇß´Ù.
 
Á¤ ±³¼ö´Â “À̹ø ³í¹®Àº ¾Ç¼º ³úÁ¾¾ç ƯÀÌ ¹ÙÀÌ¿À¸¶Ä¿¸¦ ¹ß±¼ÇÏ°í ³úÁ¾¾ç ¾Ï¼¼Æ÷¿¡ ¼±ÅÃÀûÀ¸·Î ¾à¹°À» Àü´ÞÇÏ´Â ³ª³ë-¾à¹°Àü´Þ±â¼ú °³¹ß¿¡ ¼º°øÇÑ ¿¬±¸”¶ó¸ç “ÇØ´ç ±â¼úÀ» È°¿ëÇÑ Ç×¾Ï-³ª³ë¾à¹° °³¹ßÀ» ÅëÇØ ³úÁ¾¾ç ¾Ï¼¼Æ÷¿¡¸¸ Ç׾Ͼ๰À» Ç¥Àû Àü´ÞÇÏ¿© Ç×¾ÏÈ¿°ú ÁõÁø¿¡ ±â¿©ÇÏ´Â °ÍÀ» ¸ñÇ¥·Î ÇÏ°í ÀÖ´Ù”°í ¿¬±¸ ÀÇÀǸ¦ ¼³¸íÇß´Ù. 
 
ÇÑÆí, ÇØ´ç ±â¼úÀº °í·Á´ëÇб³ »êÇÐÇù·Â´Ü ¿ì¼ö ±â¼ú·Î¼­ ÇöÀç ´Ù¼öÀÇ Á¦¾à»ç¿Í ±â¼ú»ç¾÷È­¸¦ À§ÇÑ ³íÀǸ¦ ÁøÇà ÁßÀÌ´Ù.

ÀÌ ´º½ºÅ¬¸®ÇÎÀº BKT´º½º{www.bktimes.net}¿¡¼­ ¹ßÃéµÈ ³»¿ëÀÔ´Ï´Ù.